am0c16714_si_001.pdf (972.83 kB)
Download fileCollagen-Based Thiol–Norbornene Photoclick Bio-Ink with Excellent Bioactivity and Printability
journal contribution
posted on 2021-02-01, 05:33 authored by Kai Guo, Heran Wang, Shijie Li, Hui Zhang, Song Li, Huixuan Zhu, Zhenda Yang, Liming Zhang, Peng Chang, Xiongfei ZhengAs
the essential foundation of bioprinting technology, cell-laden
bio-ink is confronted with the inevitable contradiction between printability
and bioactivity. For example, type I collagen has been widely applied
for its excellent biocompatibility; however, its relatively low self-assembly
speed restricts the performance in high-precision bioprinting of cell-laden
structures. In this study, we synthesize norbornene-functionalized
neutral soluble collagen (NorCol) by the reaction of acid-soluble
collagen (Col) and carbic anhydride in the aqueous phase. NorCol retains
collagen triple-helical conformation and can be quickly orthogonally
cross-linked to build a cell-laden hydrogel via a cell-friendly thiol-ene
photoclick reaction. Moreover, the additional carboxyl groups produced
in the reaction of carbic anhydride and collagen obviously improve
the solubility of NorCol in neutral buffer and miscibility of NorCol
with other polymers such as alginate and gelatin. It enables hybrid
bio-ink to respond to multiple stimuli, resulting in continuous cross-linked
NorCol networks in hybrid hydrogels. For the first time, the collagen
with a triple helix structure and gelatin can be mixed and printed,
keeping the integrity of the printed construct after gelatin’s
dissolution. The molecular interaction among giant collagen molecules
allows NorCol hydrogel formation at a low concentration, which leads
to excellent cell spreading, migration, and proliferation. These properties
give NorCol flexible formability and excellent biocompatibility in
temperature-, ion-, and photo-based bioprinting. We speculate that
NorCol is a promising bio-ink for emerging demands in tissue engineering,
regenerative medicine, and personalized therapeutics.